A clinically applicable gene expression-based score predicts resistance to induction treatment in acute myeloid leukemia.

ABSTRACT: Prediction of resistant disease at initial diagnosis of acute myeloid leukemia (AML) can be achieved with high accuracy using cytogenetic data and 29 gene expression markers (Predictive Score 29 Medical Research Council; PS29MRC). Our aim was to establish PS29MRC as a clinically usable assay by using the widely implemented NanoString platform and further validate the classifier in a more recently treated patient cohort. Analyses were performed on 351 patients with newly diagnosed AML intensively treated within the German AML Cooperative Group registry. As a continuous variable, PS29MRC performed best in predicting induction failure in comparison with previously published risk models. The classifier was strongly associated with overall survival. We were able to establish a previously define

SUBMITTER: Moser C 

PROVIDER: S-EPMC8759116 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature